Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 4/20 | 0.43 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 5/20 | 0.40 |
| ▸ | KDM4A | O75164 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ACACB | O00763 | 1/20 | 0.38 |
| ▸ | ACACA | Q13085 | 1/20 | 0.38 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.38 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.38 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12788315 | 0.83 | ACSS2 (0.46) | BRD4MEN1NPC1RAB9AKMT2A | |
| SCHEMBL12789334 | 0.80 | ALDH1A1 (0.37) | HDAC1MEN1NPC1KMT2AHDAC10 | |
| SCHEMBL12788338 | 0.78 | CA12 (0.43) | BRD4MEN1NPC1GAARAB9A | |
| SCHEMBL12788335 | 0.77 | BRD4 (0.45) | BRD4HDAC1MEN1RAB9AKMT2A | |
| SCHEMBL12789420 | 0.77 | KDM4E (0.44) | MEN1KMT2ACYP2D6 | |
| SCHEMBL12789332 | 0.77 | KDM4E (0.39) | HDAC1MEN1NPC1KMT2AHDAC10 | |
| SCHEMBL12788535 | 0.75 | ACSS2 (0.44) | BRD4MEN1NPC1GAARAB9A | |
| SCHEMBL12788860 | 0.73 | POLB (0.44) | HDAC1MEN1KMT2AHDAC6 | |
| SCHEMBL12788464 | 0.73 | IP6K1 (0.47) | MEN1NPC1GAARAB9AKMT2A | |
| SCHEMBL3656297 | 0.72 | DDB1 (0.57) | BRD4GRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110065671-A1 | BICYCLIC HETEROCYCLE DERIVATIVES AND USE THEREOF AS GPR119 MODULATORS | MERCK SHARP & DOHME CORP. | 2011-03-17 | — | — | US | disclosed |
| US-20110065671-A1 | BICYCLIC HETEROCYCLE DERIVATIVES AND USE THEREOF AS GPR119 MODULATORS | MERCK SHARP & DOHME CORP. | 2011-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065671-A1 | BICYCLIC HETEROCYCLE DERIVATIVES AND USE THEREOF AS GPR119 MODULATORS | GPR119, GPR39, GPR65 | BRD4 563/4885GRM2 226/4885NAMPT 1635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.